Company Overview and News
* K92 MINING - MINING, PROCESSING AND EXPLORATION OPERATIONS CONTINUE AS PER NORMAL BUSINESS OPERATIONS AT K92‘S KAINANTU GOLD MINE Source text for Eikon: Further company coverage:
Above are my Top 20 gold mining stocks for 2018. All of these companies have large resources and are highly undervalued based on their cash flow potential at higher gold prices. They are on this list primarily because of their upside potential. These are either producers or development stocks, although there is one optionality play (Goldmining Inc).
BRITISH COLUMBIA, VANCOUVER--(Marketwired - Nov. 21, 2017) - K92 Mining Inc. ("K92") (TSX VENTURE:KNT)(OTCQB:KNTNF) is pleased to report it has received warrant exercises with a value in excess of $2 million during the past 10 days.
K92 Mining Inc. ("K92") (TSX VENTURE:KNT)(OTCQB:KNTNF) is pleased to announce it has intersected high grades of gold and copper mineralization in exploration drilling designed to follow up on the initial discovery of the northern extension of the Kora vein.
K92 Mining Inc. ("K92") (TSX VENTURE:KNT)(OTCQB:KNTNF) is pleased to announce results from the next five exploration holes drilled from an underground cuddy following on from the first four holes previously reported on October 17, 2017 (see Table 1.0).
K92 Mining Inc. ("K92") (TSX VENTURE:KNT)(OTCQB:KNTNF) is pleased to report that field work in the Blue Lake area of EL470 has resulted in the identification of a new, highly prospective exploration area.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 25, 2017) - K92 Mining Inc. ("K92 Mining" or the "Company") (TSX VENTURE:KNT)(OTCQB:KNTNF) announces that on October 23, 2017, the Company granted a total of 3,220,000 incentive stock options to employees, officers and directors. The options were granted in accordance with the terms of the Company's stock option plan. They are exercisable at a price of C$0.
K92 Mining Inc. ("K92") (TSX VENTURE:KNT)(OTCQB:KNTNF) is pleased to announce it has completed treating an initial 2,050 tonne bulk sample from the interpreted Kora vein, and has final results from treating this material (initial results describing the treatment of the first 800 tonnes of the bulk sample are stated in K92 News Release dated October 11, 2017).
K92 Mining Inc. ("K92") (TSX VENTURE:KNT)(OTCQB:KNTNF) is pleased to announce that the first four exploration holes drilled from an underground cuddy to follow up on the discovery of the northern extension of the Kora Vein have all intersected Kora mineralization, including high grades of copper, gold and silver (see Table 1.0).
K92 Mining Inc. ("K92") (TSX VENTURE:KNT)(OTCQB:KNTNF) is pleased to announce it has commenced treating an initial 2,000 tonne bulk sample from the interpreted Kora vein, and has results from treating the first 800 tonnes of material.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 6, 2017) - K92 Mining Inc. (TSX VENTURE:KNT)(OTCQB:KNTNF) ("K92") is pleased to announce the appointment of Mr. Chris Muller, PhD as Vice-President, Exploration and Mr. Gavin Ferguson as Senior Vice President Operations.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 6, 2017) - Remo Resources Inc. (TSX VENTURE:RER) (the "Company" or "Remo"), a Tier 2 mining issuer listed on the TSX Venture Exchange (the "Exchange"), is pleased to announce that it has signed an Amalgamation Agreement dated October 5, 2017 (the "Agreement") with Chakana Copper Corp. ("Chakana"), a private British Columbia corporation, whereby Remo will acquire all of the outstanding shares of Chakana (the "Proposed Transaction") in exchange for common shares of Remo.
K92 Mining Inc. ("K92") (TSX VENTURE:KNT)(OTCQB:KNTNF) is pleased to announce it has commenced mining an initial 2,000 tonne bulk sample from the interpreted Kora vein, mining along strike in a northerly and southerly direction from the crosscut.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET